Korro Bio, Inc., a biopharmaceutical firm based in Cambridge, Massachusetts, is dedicated to exploring, advancing, and bringing to market genetic therapeutics. These ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-1.26 · Revenue $187500.00 · 8 analysts
Est. EPS $-1.29 · Revenue $187500.00 · 8 analysts
Est. EPS $-5.31 · Revenue $333333.00 · 9 analysts
Est. EPS $-1.04 · Revenue $500000.00 · 3 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $6.4M | +181.5% | — |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-117.3M | -40.3% | +3.6% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +33.0% | -67.0% | — |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -1366.4% | +66.2% | — |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -1834.5% | +50.2% | — |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-79.1M | -1.4% | -5.8% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -1237.2% | +64.0% | — |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 84.5% | +202.9% | +14.1% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 6.90x | -21.5% | +17.6% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $113.5M | -49.8% | -11.0% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -12.48 vs -9.03 | -38.2% | -1.07 vs -1.34 | +20.0% |
| Revenue Surprise | $6.4M vs $5.5M | +15.8% | $0 vs $214286 | -100.0% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 26, 2026 | FORMELA JEAN FRANCOIS | director | Common Stock | D | 249 | $13.96 |
| Aug 26, 2026 | FORMELA JEAN FRANCOIS | director | Common Stock | D | 51 | $13.96 |
| Aug 19, 2026 | FORMELA JEAN FRANCOIS | director | Common Stock | D | 23,584 | $14.00 |
| Aug 19, 2026 | FORMELA JEAN FRANCOIS | director | Common Stock | D | 4,884 | $14.00 |
| Aug 11, 2026 | FORMELA JEAN FRANCOIS | director | Common Stock | D | 1,775 | $13.96 |
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Ram Aiyar | Chief Executive Officer, President, Interim Chief Financial Officer, Principal Financial Officer & Director | USD 852,656 | Male | 1978 | Active |
Loic Vincent | Chief Scientific Officer | USD 642,518 | — | — | Active |
Jeffrey Cerio | Senior Vice President, General Counsel & Corporate Secretary | USD 587,500 | Male | — | Active |
Jean-Francois Formela | Co-Founder & Director | USD 51,500 | — | 1957 | Active |
Andrew Fraley | Co-Founder & Advisor | — | Male | — | Active |
Joshua Rosenthal | Co-Founder & Advisor | — | — | — | Active |
Gaozhong Zhu | SVP of Chemistry, Manufacturing and Controls & Technical Operations | — | — | — | Active |
Oliver Dolan | Senior Vice President of Finance & Principal Accounting Officer | — | Male | 1983 | Active |
Todd Chappell | Chief Operating Officer | — | Male | 1973 | Active |
Stephanie Engels | Chief People Officer | — | Female | — | Active |
CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, President & Chief Executive Officer will participate in the following investor conferences:
Korro Bio, Inc. (NASDAQ: KRRO - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the twelve analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation, six have issued a buy recommendation and three have assigned a
CAMBRIDGE, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of a non-statutory stock option to one newly hired employee.
Korro Bio, Inc. (KRRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical trial in second half of 2026 Received Orphan Drug Designation from the European Medicines Agency (EMA) for KRRO-121 for patients with urea cycle disorders (UCDs) Nominated KRRO-111 as development candidate for the treatment of Alpha-1 Antitrypsin Deficiency (AATD); potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungs Ended second quarter 2026 with $137.9 million in cash, cash equivalents and marketable securities; provides sufficient resources to achieve value inflection points for multiple RNA editing programs including clinical data for KRRO-121 and KRRO-111; cash runway into the second half of 2028 CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today reported results for the second quarter ended June 30, 2026, and provided a corporate update.
